Telstar Group and Puretech Process Systems are teaming up to meet the flood of pharma and biotech demand for water treatment technologies.
Under the new Telstar Puretech brand the companies will offer global integrated solutions for cGMP water systems under one brand. This will include raw water pre-treatment, purified water, water for injection, and pure steam. The pact will also provide water storage and distribution services.
Jorge Domingo, Telstar Puretech’s technical product manager, explained to in-PharmaTechnologist.com that Spain-based Telstar will contribute its in-house sterilisation, freeze drying, containment and clean air technologies, while UK firm, Puretech, will manufacture its purified water systems and provide water storage and distribution services.
Domingo said: “Telstar Group and Puretech are fully committed to face all potential business together as partners, whatever business line or branch of Telstar is involved.”
He claimed that Telstar’s well developed sales position in Asia-Pacific and the Americas will allow Puretech to geographically expand its network of network of offices, agents and distributors in these major markets.
Simultaneously, Telstar will stand to gain from Puretech’s relationships with drug giants, GlaxoSmithKline, Astra-Zeneca, Schering Plough and Novartis.
Domingo pointed out that the deal sets out to address a rising demand for purified water in the pharma and biopharma industries and emerging markets.
“Demand is growing significantly in emerging markets where pharmaceutical and biotech industries are moving to, but EU and US laboratories are also replacing obsolete equipment with leading edge technologies,” he said.
Drowning in demand in emerging countries
This echoes the thoughts of David Rose, VP of equity research in water and renewable energies at Wedbush Securities.
Rose said global water issues and an increase in demand for clean water in emerging markets is urging industrial companies to invest in or develop ways of improving water quality and efficiency to enhance growth rates.
He cited Pall Corp, a global filtration, separation and purification technology provider which caters for the life sciences industry, as one investor benefiting from the influx in demand for water efficiency and quality solutions.
“Pall Corp. provides filters to a variety of different industries, and it’s a really fluid company,” said Rose, adding: “The life sciences or the biopharmaceutical industry needs pure water, hospitals need pure water - about 40 per cent of their business is in the life sciences area. They’ve experienced a significant amount of growth from emerging markets.”
DSM develops and manufactures Ferritin for BiAqua
In other news, DSM BioSolutions and BiAqua have inked a deal for strain and process development and production of BiAqua Ferritin for BiAqua’s core technology to address bio-fouling and arsenic contamination in the water sector.
The Biaqua Ferritin will be used for BiAqua water contamination studies in collaboration with water companies and consumers worldwide to reduce bacterial and arsenic contamination.
DSM has begun strain and process development of BiAqua’s Ferritin product at its facility in Delft, the Netherlands. The firm said scale-up and manufacturing of the bio-based solution will soon commence at its microbial fermentation biotech facility in Capua, Italy.